SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Small Cap Foreign Biotech
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RWReeves who started this subject11/10/2000 5:05:17 AM
From: nigel bates  Read Replies (1) of 363
 
LONDON, Nov 10 (Reuters) - UK biotechnology firm PPL Therapeutics Plc (LSE: PTH.L - news) said on Friday it was extending its technology platform into diabetes treatment, and would create a new unit to focus on this, which could be separately listed in the future.
The diabetes project would focus on the conversion of human stem cells into insulin producing islet cells which, as had been given considerable credibility by recent advances in Canada, the company said.
"Forming a subsidiary company will facilitate the acquisition of certain key third parties...which will be essential in achieving the production of the human insulin producing islet cells," PPL said in a statement.
"PPL is already in contact with some relevant third parties," the company said....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News